| Half-life | 32 hours |
| Tmax | 4.5 h |
| Bioavailability | 50 % (approx) |
| Protein Binding | 97 % |
| Volume of Distribution | 17 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Higher serotonergic activity vs other TCAs; monitor ECG due to QT and arrhythmia risk. |
Severity: Severe
Adverse Effects:
Sexual dysfunction, weight gain, constipation, arrhythmias, seizure threshold lowering
Contraindications:
Concurrent MAOI use, recent MI
Precautions:
Monitor ECG; caution in epilepsy; dose titration essential.